Dr. Riess Discusses PD-L1 Expression in Thymic Malignancies

Jonathan Riess, MD, MS
Published: Thursday, Aug 07, 2014

Jonathan Riess, MD, MS, Assistant Professor of Medicine, Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses PD-L1 expression in a thymoma tissue microarray.

As PD-1 and PD-L1 antibodies have demonstrated benefit in other tumor types, Riess says, researchers are curious to analyze these agents for the treatment of thymic malignancies. This analysis was conducted to evaluate thymoma expression of PD-L1, which is a biomarker for response to PD-1 and PD-L1 antibodies.

Results showed that all thymic tumors expressed PD-L1 to some degree, lending support for a clinical trial looking at PD-1 and PD-L1 antibodies in this space.

Jonathan Riess, MD, MS, Assistant Professor of Medicine, Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses PD-L1 expression in a thymoma tissue microarray.

As PD-1 and PD-L1 antibodies have demonstrated benefit in other tumor types, Riess says, researchers are curious to analyze these agents for the treatment of thymic malignancies. This analysis was conducted to evaluate thymoma expression of PD-L1, which is a biomarker for response to PD-1 and PD-L1 antibodies.

Results showed that all thymic tumors expressed PD-L1 to some degree, lending support for a clinical trial looking at PD-1 and PD-L1 antibodies in this space.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x